Avexitide (Eiger Biopharmaceuticals), a first-in-class GLP-receptor blocker, significantly reduced hypoglycemia in patients with refractory post-bariatric hypoglycemia, new research finds. Post-bariatric hypoglycemia is a complication of […]
Patients with advanced classical Hodgkin lymphoma treated with first line brentuximab vedotin (Adcetris) plus chemotherapy showed substantial improvements in overall survival compared with those receiving standard […]
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.